A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1

Journal of Infectious Diseases

Volumn 199, Issue 11, 2009, Pages 1638-1647

  Saag, Michael ^a,g   Goodrich, James ^b   Fätkenheuer, Gerd ^c   Clotet, Bonaventura ^d   Clumeck, Nathan ^e   Sullivan, John ^f   Westby, Mike ^f   Van Der Ryst, Elna ^f   Mayer, Howard ^b  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^f PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYTOCHROME P450 3A4; DELAVIRDINE; ENFUVIRTIDE; MARAVIROC; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BRONCHITIS; CD4 LYMPHOCYTE COUNT; CHORIORETINITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ENCEPHALITIS; ESOPHAGUS CANDIDIASIS; FATIGUE; FEMALE; HERPES VIRUS INFECTION; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INJECTION SITE REACTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOBACTERIOSIS; NAUSEA; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADULT; AGED; CYCLOHEXANES; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HIV; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; PATIENT SELECTION; PHENOTYPE; PLACEBOS; TRIAZOLES; VIRAL LOAD; YOUNG ADULT;

EID: 67650694310     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/598965     Document Type: Article

References (13)

1. Berger EA, Doms RW, Fenyo EM, et al. A new classification for HIV-1. Nature 1998; 391:240.
2. Whitcomb JM, Huang W, Fransen S, et al. Analysis of baseline enfuvirtide (T20) susceptibility and co-receptor tropism in two phase III study populations [abstract 557]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). 2003.
3. Coakley E, Benhamida J, Chappey C, et al. An evaluation of tropism profiles and other characteristics among 3988 individuals screened for the A4001026, A400102 (MOTIVATE 1) and A4001028 (MOTIVATE 2) studies for maraviroc [abstract 8]. In: Program and abstracts of the 2nd International Workshop on Targeting HIV Entry (Boston). 2006.
4. Wilkin TJ, Su Z, Kuritzkes DR, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007: 44:591-5.
5. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857): a potent, orally bioavailable and selective small-molecule inhibitor of the chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005: 49: 4721-32.
6. Fätkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005: 11:1170-2.
7. Gulick R, Lalezari J, Goodrich J, et al.; MOTIVATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-41.
8. Fatkenheuer G, Nelson M, Lazzarin A, et al.; for the MOTIVATE 1 and MOTIVATE 2 Study Teams. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359:1442-55.
9. Silvestri G, Paiardini M, Pandrea I, Lederman MM, Sodora DL Understanding the benign nature of SIV infection in natural hosts. J Clin Invest 2007; 117:3148-54.
10. Hammer SM, Eron JJ Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-70.
11. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007; 196:304-12.
12. Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51:566-75.
13. Westby M, Lewis M, Whitcomb JM, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants inaminorityof HIV- 1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006;80:4909-20.